NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.
The completion of manufacturing for the oral gummy formulation marks a significant milestone for NanoViricides, as it moves closer to initiating patient dosing in the planned Phase II trial. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral that has shown effectiveness in animal models against monkeypox (Mpox), smallpox, measles, RSV, COVID-19, and influenza. The successful Phase I study reported no adverse events in healthy volunteers, supporting the progression to Phase II.
The upcoming presentation at the NIBA conference provides an opportunity for NanoViricides to update investors on its clinical development plans and strategic initiatives. The company's unique nanomaterial-based platform aims to create targeted antiviral therapies with broad-spectrum activity, potentially addressing multiple viral infections with a single drug candidate.
NanoViricides is a clinical stage company focused on creating special purpose nanomaterials for antiviral therapy. In addition to NV-387, the company is developing NV-HHV-1 for herpesvirus infections including HSV-1, HSV-2, VZV shingles, and chickenpox. The company cannot project an exact date for filing an IND for any of its drugs due to dependence on external collaborators and consultants.
For more information, visit the company's newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/AILOVA.
